SCHEMBL6796090

SCHEMBL6796090

CCCCCCN(C)c1ccc(C=C2SC(=S)N(CC(=O)NS(=O)(=O)C(F)(F)F)C2=O)cc1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 4/20 0.47
▸ MEN1 O00255 3/20 0.47
▸ L3MBTL1 Q9Y468 2/20 0.47
▸ ATM Q13315 1/20 0.45
▸ PTPN12 Q05209 1/20 0.43
▸ PTPN22 Q9Y2R2 1/20 0.43
▸ MAPT P10636 2/20 0.43
▸ NPSR1 Q6W5P4 1/20 0.43
▸ KDM4E B2RXH2 1/20 0.42
▸ MAPK1 P28482 1/20 0.42
▸ POLB P06746 1/20 0.42
▸ DNM1 Q05193 1/20 0.42
▸ AKR1B1 P15121 2/20 0.41
▸ PTPN1 P18031 2/20 0.41
▸ MMP3 P08254 1/20 0.41
▸ MMP13 P45452 1/20 0.41
▸ CRHBP P24387 1/20 0.41
▸ CRHR2 Q13324 1/20 0.41
▸ PPARG P37231 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6798631 1.00 KMT2A (0.47) KMT2AMEN1L3MBTL1ATMPTPN12
SCHEMBL6787173 0.90 KMT2A (0.48) KMT2AMEN1L3MBTL1ATMPTPN12
SCHEMBL6787171 0.90 KMT2A (0.48) KMT2AMEN1L3MBTL1ATMPTPN12
SCHEMBL6789990 0.89 KMT2A (0.48) KMT2AMEN1L3MBTL1ATMPTPN12
SCHEMBL6789993 0.89 KMT2A (0.48) KMT2AMEN1L3MBTL1ATMPTPN12
SCHEMBL6792437 0.86 KMT2A (0.51) KMT2AMEN1L3MBTL1ATMPTPN12
SCHEMBL6785574 0.86 KMT2A (0.51) KMT2AMEN1L3MBTL1ATMPTPN12
SCHEMBL6796080 0.86 KMT2A (0.51) KMT2AMEN1L3MBTL1ATMPTPN12
SCHEMBL6903655 0.86 KMT2A (0.51) KMT2AMEN1L3MBTL1ATMPTPN12
SCHEMBL6791768 0.85 PTPN12 (0.60) KMT2AMEN1PTPN12PTPN22MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1192144-A1 RHODANINE DERIVATIVES AND THEIR USE IN INHIBITING AND IMAGING AMYLOIDS WARNER-LAMBERT COMPANY (US) 2002-04-03 — — EP claimed
WO-2000076988-A1 RHODANINE DERIVATIVES AND THEIR USE IN INHIBITING AND IMAGING AMYLOIDS WARNER-LAMBERT COMPANY (US) 2000-12-21 — — WO claimed
US-20040197268-A1 Method of imaging amyloid deposits using substituted rhodanine derivatives AUGELLI-SZAFRAN CORINNE ELIZAB (US) 2004-10-07 — — US disclosed
EP-1192144-A1 RHODANINE DERIVATIVES AND THEIR USE IN INHIBITING AND IMAGING AMYLOIDS WARNER-LAMBERT COMPANY (US) 2002-04-03 — — EP disclosed
WO-2000076988-A1 RHODANINE DERIVATIVES AND THEIR USE IN INHIBITING AND IMAGING AMYLOIDS WARNER-LAMBERT COMPANY (US) 2000-12-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040197268-A1 Method of imaging amyloid deposits using substituted rhodanine derivatives APP, PSEN1, PSEN2 KMT2A 4348/4885MEN1 360/4885L3MBTL1 4403/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback